Cdc25C is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

Shahan Mamoor, MS¹

¹shahanmamoor@gmail.com

East Islip, NY USA

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2)¹ utilized for the treatment of adjuvant and metastatic breast cancer² in the United States and worldwide. We mined published microarray and gene expression data^{3,4} to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We identified the activator of the maturation-promoting factor, CDC25C⁵⁻¹² as among the genes most differentially expressed in the primary tumors of patients with breast cancer treated with trastuzumab. The primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of CDC25C messenger RNA than did patients not treated with trastuzumab, and a single administration of trastuzumab was sufficient to result in differential expression of CDC25C in primary tumors of the breast, demonstrating that a critical component of the cellular machinery that facilitates progression of cells through mitosis⁵⁻¹² is likely transcriptionally induced in primary tumors of the breast by trastuzumab.

Keywords: trastuzumab, breast cancer, CDC25C, systems biology of breast cancer, targeted therapeutics in breast cancer.

The mechanism of action ascribed to trastuzumab function is thought to be binding of the F_{ab} domain of trastuzumab to the extracellular region of the human epidermal growth factor receptor 2 (HER2)¹, but the transcriptional consequences resulting from signaling downstream of trastuzumab binding to HER2 is less well understood. Through unbiased, systems-level comparative transcriptome analysis of published microarray and gene expression data^{3,4}, we report here that CDC25C is a differentially expressed gene in the tumors of trastuzumab-treated patients: patients treated with trastuzumab expressed significantly higher levels of CDC25C than did those of patients not treated with trastuzumab.

Methods

We used datasets GSE38057³ and GSE114082⁴ this differential gene expression analysis of the transcriptional response to trastuzumab treatment in patients with breast cancer. GSE38057 was generated using DASL Human Cancer Panel by Probe technology with $n=6$ primary breast tumors from patients treated with induction chemotherapy and/or hormone therapy without trastuzumab and $n=35$ primary breast tumors from patients treated with induction chemotherapy and/or hormone therapy in addition to trastuzumab, both of which developed brain metastases; analysis was performed using platform GPL5826. GSE114082 was generated using Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip technology with $n=17$ primary breast tumors from patients before trastuzumab treatment and $n=17$ primary tumors from patients after trastuzumab treatment, analysis performed using platform GPL14951. The Benjamini and Hochberg method of p -value adjustment was used for ranking of differential expression but raw p -values were used to assess statistical significance of global or multiplexed differential expression. Log-transformation of data was auto-detected, and the NCBI generated category of platform annotation was used. A statistical test was performed to evaluate whether CDC25C gene expression was significantly between primary breast tumors of patients receiving trastuzumab using a two-tailed, unpaired t-test with Welch's correction. We used PRISM for all statistical analyses of differential gene expression in human breast cancer (Version 8.4.0)(455).

Results

We harnessed the power of blind, comparative transcriptome analysis using published microarray and gene expression data^{3,4} to identify the most significant transcriptional features of the primary breast tumors of patients treated with trastuzumab (Herceptin).

CDC25C is differentially expressed in the tumors of patients treated with trastuzumab.

We identified the tyrosine phosphatase and maturation-promoting factor activator Cdc25C as among the genes whose expression changed most significantly in the tumors of breast cancer patients treated with trastuzumab in a multiplexed gene expression dataset³ (Table 1). When sorting each of the genes expressed in the primary tumors of breast cancer patients treated with trastuzumab based on significance of change as compared to that of patients not treated with trastuzumab, CDC25C ranked 18 out of 1506 total transcripts (Table 1), equating to 98.8% differential expression. CDC25C differential expression in the tumors of patients treated with trastuzumab was statistically significant (Table 1; $p=0.02502$).

The first dataset, although measuring the expression of over 1500 genes, was still limited. We turned to a second microarray dataset⁴, this measuring the expression of genes across the transcriptome - 29377 genes in total. The tumors compared in this dataset were sampled from the same patient before and after a single, brief exposure to trastuzumab, not comparing tumors from different patients treated with a

1 course of trastuzumab or not. Thus, while differentially expressed genes when comparing tumors based
2 on trastuzumab treatment can result from a variety of sources, including gene expression changes
3 resulting from tumor evolution over the course of treatment, changes identified in this dataset, occurring
4 after only a single treatment of trastuzumab, are more likely to be a direct transcriptional result of
5 trastuzumab binding events. We found again that CDC25C was among the genes most differentially
6 expressed in the tumors of patients administered a single treatment of trastuzumab (Table 2). When
7 sorting each of the genes expressed in the tumors of patients administered a single treatment of
8 trastuzumab, CDC25C ranked 781 out of 29377 total transcripts (Table 2), equating to 97.3% differential
9 expression. Differential expression of CDC25C in the primary tumors of breast cancer patients following
10 treatment with trastuzumab was statistically significant (Table 2; $p=3.77E-05$).

11 **CDC25C is expressed at significantly higher levels in the tumors of breast cancer patients treated**
12 **with trastuzumab than in the tumors of those not treated with trastuzumab.**

13 We obtained exact mRNA expression levels for CDC25C from tumors of patients treated with
14 trastuzumab and from the tumors of patients not treated with trastuzumab to directly evaluate magnitude
15 and change of expression in CDC25C based on history of trastuzumab treatment. CDC25C was
16 expressed at higher levels in the tumors of patients treated with trastuzumab as compared to those of
17 patients not treated with trastuzumab, and this difference was statistically significant (Figure 1;
18 $p=0.0003$). We calculated a mean fold change of 1.54 ± 0.64 in CDC25C expression in the primary
19 tumors of patients treated with trastuzumab relative to that of patients not treated with trastuzumab.

20 Thus, we found using published multiplexed gene expression and microarray data^{3,4} that CDC25C
21 was among the genes most differentially expressed in the tumors of patients treated with trastuzumab, that
22 CDC25C was expressed at significantly higher levels in the tumors of patients treated with trastuzumab as
23 compared to those not treated with trastuzumab, and that this transcriptional change was likely a direct
24 result of trastuzumab treatment as opposed to a gene expression change associated with clonal selection
25 and evolution of the tumor across the course of treatment.

26 **Discussion**

27 We provided evidence here that Cdc25C, a tyrosine phosphatase that activates that maturation-
28 promoting factor is a differentially expressed gene in the tumors of patients treated with trastuzumab, and
that the primary tumors of breast cancer patients treated with trastuzumab expressed higher levels of
CDC25C in their primary tumors than did patients not treated with trastuzumab. Thus, a direct
transcriptional consequence of trastuzumab administration in patients with breast cancer is the induction,
in primary tumors of the breast, of cellular machinery that licenses progression through the cell cycle⁵⁻¹².

References

1. Hudis, C.A., 2007. Trastuzumab—mechanism of action and use in clinical practice. *New England Journal of Medicine*, 357(1), pp.39-51.
2. Herceptin (Trastuzumab). Indications. <https://www.herceptin.com/hcp/indications.html>.
3. Duchnowska, R., Jassem, J., Goswami, C.P., Dundar, M., Gökmen-Polar, Y., Li, L., Woditschka, S., Biernat, W., Sosińska-Mielcarek, K., Czartoryska-Arłukowicz, B. and Radecka, B., 2015. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. *Journal of Neuro-oncology*, 122(1), pp.205-216.
4. Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M.R., Di Modica, M., Paolini, B., Lollini, P.L., Di Cosimo, S., Sfondrini, L., Generali, D. and Tagliabue, E., 2018. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. *British journal of cancer*, 119(12), pp.1487-1494.
5. Dunphy, W.G. and Kumagai, A., 1991. The cdc25 protein contains an intrinsic phosphatase activity. *Cell*, 67(1), pp.189-196.
6. Gautier, J., Solomon, M.J., Booher, R.N., Bazan, J.F. and Kirschner, M.W., 1991. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. *Cell*, 67(1), pp.197-211.
7. Kumagai, A. and Dunphy, W.G., 1991. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. *Cell*, 64(5), pp.903-914.
8. Kawabe, T., Suganuma, M., Ando, T., Kimura, M., Hori, H. and Okamoto, T., 2002. Cdc25C interacts with PCNA at G2/M transition. *Oncogene*, 21(11), pp.1717-1726.
9. Kuang, J.I.A.N., Ashorn, C.L., Gonzalez-Kuyvenhoven, M. and Penkala, J.E., 1994. cdc25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor. *Molecular Biology of the Cell*, 5(2), pp.135-145.
10. Forester, C.M., Maddox, J., Louis, J.V., Goris, J. and Virshup, D.M., 2007. Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1. *Proceedings of the National Academy of Sciences*, 104(50), pp.19867-19872.
11. Izumi, T. and Maller, J.L., 1993. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. *Molecular biology of the cell*, 4(12), pp.1337-1350.
12. Bahassi, E.M., Hennigan, R.F., Myer, D.L. and Stambrook, P.J., 2004. Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation. *Oncogene*, 23(15), pp.2658-2663.

Rank	ID	p-value	t	B	FC	Gene
18	GI_12408657-A-4	0.02502	2.322414	-4.26	1.54 ± 0.64	CDC25C

Table 1: CDC25C is differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab.

The rank of differential expression, probe ID, p-value with respect to global differential expression, t, a moderated t-statistic, B, the log-odds of differential expression between the two groups compared, fold change of expression in CDC25C between the tumors of patients treated with trastuzumab and the tumors of patients not treated with trastuzumab, and gene are listed in this chart.

Rank	ID	p-value	t	B	Gene
781	ILMN_2294431	3.77E-05	-4.7004687	2.17529	CDC25C

Table 2: A single exposure to trastuzumab is sufficient to drive differential expression of CDC25C in the primary tumors of patients with breast cancer.

The rank of differential expression, probe ID, p-value with respect to global differential expression, t, a moderated t-statistic, B, the log-odds of differential expression between the two groups compared, gene and gene name are listed in this chart.

Figure 1: CDC25C is expressed at higher levels in the primary tumors of patients treated with trastuzumab.

The mRNA expression level of CDC25C is graphically depicted in this chart in the primary tumors of breast cancer patients not treated with trastuzumab (left) and in the primary tumors of breast cancer patients treated with trastuzumab (right), with mean mRNA expression level marked and the result of a statistical test evaluating significance of difference between CDC25C expression in the primary tumors of patients treated with trastuzumab or not, a *p*-value, listed above.